D
Darlene Veruttipong
Researcher at University of California, Los Angeles
Publications - 29
Citations - 1343
Darlene Veruttipong is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Brachytherapy & Radiation therapy. The author has an hindex of 11, co-authored 29 publications receiving 994 citations. Previous affiliations of Darlene Veruttipong include University of Michigan.
Papers
More filters
Journal ArticleDOI
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian,Aaron Lisberg,Krikor Bornazyan,Darlene Veruttipong,Jonathan W. Goldman,Silvia C. Formenti,Edward B. Garon,Percy Lee +7 more
TL;DR: This trial aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab to determine whether previous radiotherapy affected progression-free survival, overall survival, and pulmonaryoxicity in the intention-to-treat population.
Journal ArticleDOI
Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer
Aaron A. Laviana,Annette M. Ilg,Darlene Veruttipong,Hung-Jui Tan,Michael A. Burke,Douglas Niedzwiecki,Patrick A. Kupelian,Christopher R. King,Michael L. Steinberg,Chandan R. Kundavaram,Mitchell Kamrava,Alan L. Kaplan,Andrew K. Moriarity,William Hsu,Daniel Margolis,Jim C. Hu,Christopher S. Saigal +16 more
TL;DR: The results of time‐driven activity‐based costing (TDABC) for competing treatments of low‐risk prostate cancer for men with prostate cancer are reported.
Journal ArticleDOI
Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry.
Darlene Veruttipong,Amr S. Soliman,Sam J. Gilbert,Taylor Blachley,Ahmed Hablas,Mohamed Ramadan,Laura S. Rozek,Ibrahim A. Seifeldin +7 more
TL;DR: Low rate of polyps, low incidence in older subjects, and high rate of rectal cancer in Egypt, the registry data of Egypt shows a slightly higher incidence of colorectal cancer than the United States in subjects under age 40 years.
Journal ArticleDOI
Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
TL;DR: In the setting of SBRT, an elevated pretreatment NLR, PLR, and neutrophil count and the presence of lymphocytopenia independently predicted for poor OS.
Journal ArticleDOI
Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma
Kiri A. Sandler,Darlene Veruttipong,Vatche G. Agopian,Richard S. Finn,Johnny C. Hong,Fady M. Kaldas,Saeed Sadeghi,Ronald W. Busuttil,Percy Lee +8 more
TL;DR: SBRT is a promising option for patients with unresectable or recurrent cholangiocarcinoma either as a component of neoadjuvant therapy prior to OLT or as part of definitive therapy for patients who are unresectables and not eligible for transplantation.